EWTX Stock: Price, Earnings History and SEC Filings
Edgewise Therapeutics, Inc. (EWTX) last traded at $38.90, down 0.03% on the latest session and down 4.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.53 against an analyst estimate of $-0.48, a miss of 10.4%.
$38.90 -0.03%
1 month-4.19%
52-week high$48.51
52-week low$16.70
Volume967,477
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
EWTX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.53 | $-0.48 | -10.42% |
| Mar 2026 | May 7, 2026 | $-0.46 | $-0.50 | +8.00% |
| Dec 2025 | Feb 26, 2026 | $-0.47 | $-0.43 | -9.30% |
| Sep 2025 | Nov 6, 2025 | $-0.39 | $-0.40 | +2.50% |
EWTX beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for EWTX
SEC filing data is not available right now. You can search for EWTX on SEC EDGAR.
EWTX news
- Edgewise Therapeutics' Investors Focused on Upcoming Phase 3 Design for '7500 in Hypertrophic Cardiomyopathy, RBC SaysOct 27, 2026 · finance.yahoo.com
- William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates CoverageOct 21, 2026 · finance.yahoo.com
- Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?Oct 19, 2026 · finance.yahoo.com
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. (EWTX) is a US-listed public company on Nasdaq.